Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
about
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applicationsMolecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.Expression of proteinases and inhibitors in human breast cancer progression and survival.Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts.Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.Receptor-targeted nanoparticles for in vivo imaging of breast cancer.Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.Modulators of the urokinase-type plasminogen activation system for cancer.Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.Proteases as prognostic markers in human and canine cancers.Prostate cancer cell surface-associated keratin 8 and its implications for enhanced plasmin activity.Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes.Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer.Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.Tumor cells in lymph vessels and lymph nodes closely associated with nodal metastasis by invasive ductal carcinoma of the breast.
P2860
Q26865306-FC0F2E89-53D7-427F-94B1-87285CE9E633Q30410360-B15E2530-EF48-4678-B786-C9982456327BQ33919059-4206AC74-3B10-4866-91BB-F5EDE0E12B91Q34475106-D3FC6BF5-3CD0-49BA-B215-BBEEAFBAEA39Q35159014-CF8906D0-3E7D-4250-86AB-B47489A57DA7Q35574587-F678C731-62A8-4AF3-89BC-F18CF5D47C68Q35749341-4D5E1FBD-2B6B-4201-8055-91F215EC72ECQ35990029-3B7C2682-2EE8-4F4F-961F-D4BE5C5C57D3Q36616070-FE01BA8B-D570-40F7-AB7A-1AD054C126C6Q37307237-0E7593A4-F0A4-421F-AAA8-A81B0E926B54Q37386814-C5D52A7C-009C-4EC9-884C-91BCAADC30C6Q37601854-6384E580-B4AD-43AC-B7A0-C8DFBFD6DB31Q37733590-AAD4B31D-2BD3-4F13-BC3A-52A770A5C1D2Q37801943-992303FF-5229-45B5-B0FB-5817883CA35AQ37895294-83970CEE-9B5A-4E75-9100-86CED7594883Q38296878-D4B4A22F-7032-4376-B5B7-BC6B96010500Q38692304-2384EA41-4E3D-4C65-97F3-73001B4E209EQ38823174-A9BDF2CE-F7E0-4A9E-BE07-A4A0410BA9ABQ39392535-260E043C-892F-41BC-807E-40AB521EBAA2Q40515008-487E7AE0-6D5B-419B-BA57-7228A2DC6A1FQ41469380-D11AFA73-8683-4AF9-A2F1-73C7158735E4Q41826247-9449856B-B53C-4464-8709-007765469A1BQ43261947-D406E43F-B978-4374-94F7-A400523BF76AQ43907665-175EF1F1-C846-4943-ACFC-582BC139E536Q51666148-EEF237B1-68CE-46E6-B0F5-F69F02D488E5Q52575847-C3C1A09D-719C-4DB6-B17F-6BD54B6E8C14Q52841791-F86D0CD4-4D1D-4B22-86EC-E7F561407769Q53552265-168F3435-9B7E-4E3F-B0C7-1F5C72192296Q53787959-E219398F-79AF-4EBF-81EA-1BAFCC0B207D
P2860
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Immunohistochemical expression ...... ciations with tumor pathology.
@ast
Immunohistochemical expression ...... ciations with tumor pathology.
@en
type
label
Immunohistochemical expression ...... ciations with tumor pathology.
@ast
Immunohistochemical expression ...... ciations with tumor pathology.
@en
prefLabel
Immunohistochemical expression ...... ciations with tumor pathology.
@ast
Immunohistochemical expression ...... ciations with tumor pathology.
@en
P2093
P2860
P1476
Immunohistochemical expression ...... ciations with tumor pathology.
@en
P2093
P2860
P304
P356
10.1016/S0002-9440(10)64637-8
P407
P577
2000-10-01T00:00:00Z